415 reports of this reaction
3.5% of all SEVOFLURANE reports
#3 most reported adverse reaction
CARDIAC ARREST is the #3 most commonly reported adverse reaction for SEVOFLURANE, manufactured by AbbVie Inc.. There are 415 FDA adverse event reports linking SEVOFLURANE to CARDIAC ARREST. This represents approximately 3.5% of all 11,848 adverse event reports for this drug.
Patients taking SEVOFLURANE who experience cardiac arrest should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CARDIAC ARREST is moderately reported among SEVOFLURANE users, representing a notable but not dominant share of adverse events.
In addition to cardiac arrest, the following adverse reactions have been reported for SEVOFLURANE:
The following drugs have also been linked to cardiac arrest in FDA adverse event reports:
CARDIAC ARREST has been reported as an adverse event in 415 FDA reports for SEVOFLURANE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CARDIAC ARREST accounts for approximately 3.5% of all adverse event reports for SEVOFLURANE, making it one of the most commonly reported side effect.
If you experience cardiac arrest while taking SEVOFLURANE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.